Board Meeting5 Nov 2026, 04:52 pm
Venmax Drugs Board Meeting on Nov 12 to Approve Q2 FY27 Results
AI Summary
Venmax Drugs and Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for November 12, 2026. The primary agenda is to consider and approve the Unaudited Standalone Financial Results for the quarter ended September 30, 2026. The trading window for designated persons will remain closed from October 1, 2026, until 48 hours after the results are approved, closing on November 14, 2026.
Key Highlights
- Board meeting scheduled for November 12, 2026.
- To approve Unaudited Standalone Financial Results for Q2 FY27.
- Trading window closure extended until November 14, 2026.
- Results pertain to the quarter ended September 30, 2026.
Price Impact
More from VENMAX